These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523 [TBL] [Abstract][Full Text] [Related]
3. The role of KLF6 and its splice variants in cancer therapy. DiFeo A; Martignetti JA; Narla G Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929 [TBL] [Abstract][Full Text] [Related]
4. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. Liang WC; Wang Y; Xiao LJ; Wang YB; Fu WM; Wang WM; Jiang HQ; Qi W; Wan DC; Zhang JF; Waye MM RNA Biol; 2014; 11(7):845-54. PubMed ID: 24921656 [TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706 [TBL] [Abstract][Full Text] [Related]
6. Mapping of ESE-1 subdomains required to initiate mammary epithelial cell transformation via a cytoplasmic mechanism. Prescott JD; Poczobutt JM; Tentler JJ; Walker DM; Gutierrez-Hartmann A Mol Cancer; 2011 Aug; 10():103. PubMed ID: 21871131 [TBL] [Abstract][Full Text] [Related]
7. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Narla G; DiFeo A; Fernandez Y; Dhanasekaran S; Huang F; Sangodkar J; Hod E; Leake D; Friedman SL; Hall SJ; Chinnaiyan AM; Gerald WL; Rubin MA; Martignetti JA J Clin Invest; 2008 Aug; 118(8):2711-21. PubMed ID: 18596922 [TBL] [Abstract][Full Text] [Related]